Baidu
map

SCI REP-UK:乳腺癌基底亚型中,乳腺癌干细胞的转录因子网络可以控制免疫应答

2017-06-07 MedSci MedSci原创

乳腺癌是全世界妇女中最常见的癌症,并且癌细胞的转移是该疾病相关的最主要死亡原因。乳腺癌干细胞(bCSC)则被认为负责癌细胞的转移和形成化学耐药性。我们的研究结果指出了,存在于免疫监测和乳腺癌EMT活化之间的平衡的潜在的分子机制。这种分子机制可能对开发新的靶标治疗有重要意义。

乳腺癌是全世界妇女中最常见的癌症,并且癌细胞的转移是该疾病相关的最主要死亡原因。乳腺癌干细胞(bCSC)则被认为负责癌细胞的转移和形成化学耐药性。但是,目前乳腺癌干细胞(bCSC)的定义仍在争论之中。对乳腺干细胞的鉴别和分离依赖于几种乳腺CSC生物标志物和一些方法,如流式细胞术,体内致瘤模型,和组织学免疫染色等。

在这项研究中,我们基于推定的bCSC的全转录组分析和转录控制网络的逆向工程,我们鉴定了与该表型相关的两个网络。其中一个是由SNAI2,TWIST1,BNC2,PRRX1和TBX5控制的,并且形成间叶细胞或CSC样表型。第二个网络由相当于免疫应答调节剂的转录因子SCML4,ZNF831,SP140和IKZF3控制。免疫反应网络的表达与化疗的病理反应相关,并且,在基底亚型中与更好的无复发生存率相关。在患者来源的异种移植物中,这些网络在患者肿瘤中的表达预示着移植成功。因此,我们的研究结果指出了,存在于免疫监测和乳腺癌EMT活化之间的平衡的潜在的分子机制。这种分子机制可能对开发新的靶标治疗有重要意义。

原文出处:

W. A. da Silveira,S. du Manoir,D. G. Tiezzi,et al.Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype.[J].Scientific Reports.2017 June 7.DOI:10.1038/s41598-017-02761-6

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747246, encodeId=4f7d1e4724683, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 12 22:09:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935574, encodeId=865419355e47f, content=<a href='/topic/show?id=46a723e4521' target=_blank style='color:#2F92EE;'>#乳腺癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23745, encryptionId=46a723e4521, topicName=乳腺癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Aug 21 10:09:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400224, encodeId=a1951400224e5, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537469, encodeId=2f69153e4695f, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544979, encodeId=6d2915449e955, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2018-02-12 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747246, encodeId=4f7d1e4724683, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 12 22:09:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935574, encodeId=865419355e47f, content=<a href='/topic/show?id=46a723e4521' target=_blank style='color:#2F92EE;'>#乳腺癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23745, encryptionId=46a723e4521, topicName=乳腺癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Aug 21 10:09:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400224, encodeId=a1951400224e5, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537469, encodeId=2f69153e4695f, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544979, encodeId=6d2915449e955, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747246, encodeId=4f7d1e4724683, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 12 22:09:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935574, encodeId=865419355e47f, content=<a href='/topic/show?id=46a723e4521' target=_blank style='color:#2F92EE;'>#乳腺癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23745, encryptionId=46a723e4521, topicName=乳腺癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Aug 21 10:09:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400224, encodeId=a1951400224e5, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537469, encodeId=2f69153e4695f, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544979, encodeId=6d2915449e955, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747246, encodeId=4f7d1e4724683, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 12 22:09:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935574, encodeId=865419355e47f, content=<a href='/topic/show?id=46a723e4521' target=_blank style='color:#2F92EE;'>#乳腺癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23745, encryptionId=46a723e4521, topicName=乳腺癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Aug 21 10:09:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400224, encodeId=a1951400224e5, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537469, encodeId=2f69153e4695f, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544979, encodeId=6d2915449e955, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747246, encodeId=4f7d1e4724683, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 12 22:09:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935574, encodeId=865419355e47f, content=<a href='/topic/show?id=46a723e4521' target=_blank style='color:#2F92EE;'>#乳腺癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23745, encryptionId=46a723e4521, topicName=乳腺癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Mon Aug 21 10:09:00 CST 2017, time=2017-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400224, encodeId=a1951400224e5, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537469, encodeId=2f69153e4695f, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544979, encodeId=6d2915449e955, content=<a href='/topic/show?id=7a0fe1289c2' target=_blank style='color:#2F92EE;'>#癌干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71289, encryptionId=7a0fe1289c2, topicName=癌干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=340013676140, createdName=1249898am19暂无昵称, createdTime=Fri Jun 09 05:09:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]

相关资讯

ASCO:奥拉帕尼可延缓BRCA相关的转移性乳腺癌进展 ——PARP抑制剂有望在乳腺癌治疗中扮演重要角色

LBA-4:奥拉帕尼可延缓BRCA相关的转移性乳腺癌进展 ——PARP抑制剂有望在乳腺癌治疗中扮演重要角色

ASCO2017:系统治疗作为各型乳腺癌脑转移的**

所有乳腺癌脑转移患者都应当接受全身系统治疗

NEJM:奥拉帕利治疗BRCA突变的转移性乳腺癌患者疗效如何?

HER2阴性的转移性乳腺癌和BRCA突变患者中,奥拉帕尼单药治疗比标准治疗疗效更显著;中位无进展生存期延长了2.8个月,疾病进展或死亡的风险为在奥拉帕尼治疗组要比标准治疗组低42%。

ASCO 2017:乳腺癌患者的怀孕不会增加癌症复发几率

乳腺癌后妊娠的安全性依然未得到明确,特别是在激素受体阳性的女性中。2013年Azim教授在JCO杂志上发表了一篇关于激素受体情况是否影响确诊乳腺癌后怀孕患者预后的多中心回顾性研究,入组条件为确诊乳腺癌1年以上、在怀孕前无复发转移证据,分为怀孕组(确诊乳腺癌后怀孕)和对照组,研究发现怀孕并不影响激素受体阳性组(HR=0.91,95%CI=0.67-1.24,P=0.55)和激素受体阴性组(HR=0.

J Hypertens:血压和乳腺癌的风险相关吗?

该研究支持了既往的研究结果表明血压与乳腺癌之间并不存在相关性。在评估血压随着时间的推移以及评估特定的肿瘤亚型时,也可以得到类似的结论。

SCI REP: 在乳腺癌干细胞中转录因子工作网络可以调节细胞免疫应答

该研究在乳腺癌中鉴定了新的转录因子可以作为乳腺癌干细胞主要调节因子,表明这些转录因子对临床治疗效果的影响,并且证明了在免疫应答和乳腺癌的EMT激活的平衡之间存在一种可能的分子机理,这个分子机理可能有助于发展新的治疗。

Baidu
map
Baidu
map
Baidu
map